Intra Cellular Therapies reported $9K in Ordinary Share Capital for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ordinary Share Capital Change
Acadia Pharmaceuticals ACAD:US $ 0.02M 0M
ALKERMES ALKS:US $ 1.68M 0.02M
Aptinyx Inc APTX:US $ 677K 0
Biocryst Pharmaceuticals BCRX:US $ 1.86M 0.01M
Biogen BIIB:US $ 0.1M 0M
Bristol Myers Squibb BMY:US $ 292M 0M
Cytokinetics CYTK:US $ 0.08M 0M
Esperion Therapeutics ESPR:US $ 61K 0
Gilead Sciences GILD:US $ 1M 0M
Halozyme Therapeutics HALO:US $ 0.14M 0M
Intra Cellular Therapies ITCI:US $ 0.01M 0M
JAZZ PHA JAZZ:US $ 0.06M 0M
Johnson & Johnson JNJ:US $ 3120M 0M
Marinus Pharmaceuticals MRNS:US $ 0.04M 0M
Minerva Neurosciences NERV:US $ 0M 0M
Nektar Therapeutics NKTR:US $ 0.02M 0M
Novartis NVS:US $ 901M 0M
Prothena PRTA:US $ 0.47M 0M
Redhill Biopharma RDHL:US $ 1.51M 0.01M
Supernus Pharmaceuticals SUPN:US $ 0.05M 0M
United Therapeutics UTHR:US $ 0.7M 0M
Vanda Pharmaceuticals VNDA:US $ 0.06M 0M